A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age

Noris Pavia-Ruz, Miguel Angel Rodriguez Weber, Yu-Lung Lau, E Anthony S Nelson, Angkool Kerdpanich, Li-Min Huang, Peter Silas, Paul Qaqundah, Mark Blatter, Robert Jeanfreau, Paul Lei, Varsha Jain, Mohamed El Idrissi, Yang Feng, Bruce Innis, Mathieu Peeters, Jeanne-Marie Devaster, Noris Pavia-Ruz, Miguel Angel Rodriguez Weber, Yu-Lung Lau, E Anthony S Nelson, Angkool Kerdpanich, Li-Min Huang, Peter Silas, Paul Qaqundah, Mark Blatter, Robert Jeanfreau, Paul Lei, Varsha Jain, Mohamed El Idrissi, Yang Feng, Bruce Innis, Mathieu Peeters, Jeanne-Marie Devaster

Abstract

The trivalent inactivated influenza vaccine Fluarix™ is licensed in the US for adults and children from 3 years old. This randomized observer-blind study (NCT00764790) evaluated Fluarix™ at two doses; 0.25 ml (Flu-25) and 0.5 ml (Flu-50) in children aged 6-35 months. The primary objective was to demonstrate immunogenic non-inferiority vs. a control vaccine (Fluzone®; 0.25 ml). Children received Flu-25 (n = 1107), Flu-50 (n = 1106) or control vaccine (n = 1104) at Day 0 and for un-primed children, also on Day 28. Serum hemagglutination-inhibition titers were determined pre-vaccination and at Day 28 (primed) or Day 56 (un-primed). Non-inferiority was assessed by post-vaccination geometric mean titer (GMT) ratio, (upper 95% confidence interval [CI] ≤ 1.5) and difference in seroconversion rate (upper 95% CI ≤ 10%). Reactogenicity/safety was monitored. The immune response to Flu-50 met all regulatory criteria. Indicated by adjusted GMT ratios [with 95% CI], the criteria for non-inferiority of Flu-50 vs. control vaccine were reached for the B/Florida strain (1.13 [1.01-1.25]) but not for the A/Brisbane/H1N1 (1.74 [1.54-1.98]) or A/Uruguay/H3N2 (1.72 [1.57-1.89]) strains. In children aged 18-35 months similar immune responses were observed for Flu-50 and the control vaccine. Flu-50 induced a higher response than Flu-25 for all strains. Temperature (≥ 37.5°C) was reported in 6.2%, 6.4%, and 6.6% of the Flu-25, Flu-50, and control group, respectively. Reactogenicity/safety endpoints were within the same range for all vaccines. In children aged 6-35 months, immune responses with Flu-50 fulfilled regulatory criteria but did not meet the pre-defined criteria for non-inferiority vs. control. This appeared to be due to differences in immunogenicity in children aged<18 months.

Keywords: children; immunogenicity; influenza; trivalent inactivated; vaccine.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3906365/bin/hvi-9-1978-g1.jpg
Figure 1. Study flowchart showing number of children enrolled, random allocation into groups and exclusion from analyses. *ATP, according to protocol; **, one subject was administered the vaccine incorrectly and a second subject experienced an SAE considered by the investigator to be related to vaccination.

References

    1. Viboud C, Boëlle PY, Cauchemez S, Lavenu A, Valleron AJ, Flahault A, et al. Risk factors of influenza transmission in households. Br J Gen Pract. 2004;54:684–9.
    1. Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369–73. doi: 10.1086/424527.
    1. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232–9. doi: 10.1056/NEJM200001273420402.
    1. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225–31. doi: 10.1056/NEJM200001273420401.
    1. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147–52. doi: 10.1086/338363.
    1. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2012;61:613–8.
    1. Mereckiene J, Cotter S, Nicoll A, Levy-Bruhl D, Ferro A, Tridente G, et al. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill. 2008;13:19017.
    1. Public Health Agency of Canada National Advisory Committee on Immunization. Statement on seasonal influenza vaccine for 2011-2012. 2011; 37 (Accessed 30 April 2013)
    1. Usonis V, Anca I, André F, Chlibek R, Ivaskeviciene I, Mangarov A, et al. Central European Vaccination Advisory Group Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. BMC Infect Dis. 2010;10:168. doi: 10.1186/1471-2334-10-168.
    1. Steinhoff MC. Influenza in young children: burden, immunisation, and policy. Lancet Infect Dis. 2011;11:2–3. doi: 10.1016/S1473-3099(10)70263-2.
    1. UK Department of Health. Influenza. Green Book 2012; 19-v4_71 (Accessed 30 April 2013)
    1. Wright PF, Dolin R, La Montagne JR. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--II. J Infect Dis. 1976;134:633–8. doi: 10.1093/infdis/134.6.633.
    1. Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine. 2012;30:3389–94. doi: 10.1016/j.vaccine.2012.03.046.
    1. Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011;128:e276–89. doi: 10.1542/peds.2010-2777.
    1. FDA News Release. FDA approves seasonal influenza vaccine Fluarix for pediatric use; (Accessed 30 April 2013)
    1. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin. 2005;1:239–44. doi: 10.4161/hv.1.6.2376.
    1. Baxter R, Jeanfreau R, Block SL, Blatter M, Pichichero M, Jain VK, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J. 2010;29:924–30. doi: 10.1097/INF.0b013e3181e075be.
    1. Campbell JD, Chambers CV, Brady RC, Caldwell MC, Bennett NL, Fourneau MA, et al. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. Hum Vaccin. 2011;7:81–8. doi: 10.4161/hv.7.1.13553.
    1. Frank AL, Webster RG, Glezen WP, Cate TR. Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults. J Med Virol. 1981;7:135–42. doi: 10.1002/jmv.1890070207.
    1. Glezen WP, Kasel JA, Webster RG, Taber LH. Alternative approaches to immunization of children with inactivated influenza virus vaccines. J Infect Dis. 1977;136(Suppl):S677–82. doi: 10.1093/infdis/136.Supplement_3.S677.
    1. Webster RG, Glezen WP, Hannoun C, Laver WG. Potentiation of the immune response to influenza virus subunit vaccines. J Immunol. 1977;119:2073–7.
    1. Webster RG, Kasel JA, Couch RB, Laver WG. Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans. J Infect Dis. 1976;134:48–58. doi: 10.1093/infdis/134.1.48.
    1. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;16:CD004879.
    1. Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, Jain VK, et al. Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial. J Pediatric Infect Dis Soc. 2012;1:55–63. doi: 10.1093/jpids/pis012.
    1. Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, et al. The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study. Vaccine. 2012;30:7005–12. doi: 10.1016/j.vaccine.2012.09.069.
    1. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204:1879–85. doi: 10.1093/infdis/jir661.
    1. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767–77. doi: 10.1017/S0022172400022610.
    1. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18. doi: 10.1186/1471-2288-10-18.
    1. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine. 2008;26(Suppl 4):D41–4. doi: 10.1016/j.vaccine.2008.07.043.
    1. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081–5. doi: 10.1097/INF.0b013e3182367662.
    1. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012;31:745–51. doi: 10.1097/INF.0b013e31825687b0.
    1. U.S. Food and Drug Administration. FDA approves first quadrivalent vaccine to prevent seasonal influenza. February 2012. (Accessed 30 April 2013)
    1. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207:1878–87. doi: 10.1093/infdis/jit091.
    1. U.S. Department of Health and Human Services FaDA. Approval Letter- Fluarix Quadrivalent. December 14, 2012 (Accessed 30 April 2013)
    1. Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig. 2002;22:751–69. doi: 10.2165/00044011-200222110-00004.
    1. US Food and Drug Administration. Guidance for industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines 30th April 2009. (Accessed 30 April 2013)

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren